We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
Ask ADVFN Intelligence (AI)
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future...
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will...
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -5.46875 | 1.28 | 1.43 | 1.15 | 325931 | 1.30569205 | CS |
| 4 | 0.26 | 27.3684210526 | 0.95 | 1.59 | 0.7966 | 788968 | 1.15822072 | CS |
| 12 | -0.71 | -36.9791666667 | 1.92 | 2.01 | 0.7966 | 506010 | 1.18695697 | CS |
| 26 | -2.44 | -66.8493150685 | 3.65 | 6.8 | 0.7966 | 375445 | 2.28385194 | CS |
| 52 | -2.56 | -67.9045092838 | 3.77 | 6.8 | 0.7966 | 219073 | 2.49731601 | CS |
| 156 | -8.39 | -87.3958333333 | 9.6 | 10.72 | 0.7966 | 172087 | 4.30803319 | CS |
| 260 | -24.55 | -95.3027950311 | 25.76 | 95.375 | 0.7966 | 207877 | 16.69680986 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
